Drug intelligence / Profile preview

anfoxacin

Development stage: Unknown
Lead developer: Anhui Global Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

Anfoxacin is a fluoroquinolone antibiotic developed by Anhui Global Pharmaceutical. It functions by inhibiting bacterial DNA gyrase and topoisomerase IV, which are critical enzymes for DNA replication, transcription, and repair in bacteria. The drug has been investigated in Phase 2 clinical trials in China for the treatment of pyelonephritis and respiratory tract infections, often compared against established fluoroquinolones like levofloxacin.

Other names: anfoxacin hydrochloride

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on anfoxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anfoxacin.

Explore the full profile